Table 2.

miRNAs as candidate biomarkers in follicular lymphoma (FL).

miRNAs	Sample Origin	Expression	Potential Biomarker	References
miRNAs of miR-17/92 and miR-106a-363 clusters, miR-200c-3p, miR-638, miR-518a-3p	FFPE tissues	Upregulated in DLBCL vs. FL	Differential diagnosis	[53]
miR-17-5p				[54]
miR-217-5p, miR-634, miR-26b-5p		Upregulated in FL vs. DLBCL		[53]
miR-330-3p, miR-106a-5p, miR-210-3p		Upregulated in FL vs. DLBCL		[54]
miR-612, miR-188-5p, miR-302c-3p, miR-433-3p, miR-584-5p		Upregulated in BCL2+/BCL6+ and BCL2−/BCL6+ FL vs. BCL2+/BCL6− FL		[51]
miR-200a-3p, miR-135a-5p, miR-375-3p, miR-138-5p, miR-517 isomiRs		Downregulated in BCL2+/BCL6+ and BCL2−/BCL6+ FL vs. BCL2+/BCL6− FL
miR-16-5p, miR-138-5p, miR-26a-5p, miR-29c-3p		Downregulated in t(14;18)–negative FL vs. t(14;18)–positive FL		[48]
miR-193a-5p, miR-345-5p, miR-574-3p, miR-1287-5p, miR-1471	Enriched FL cells	Upregulated in FL vs. with follicular hyperplasia		[63]
miR-570-3p, miR-205-5p, miR-222-3p, miR-30a-5p, miR-301b-3p, miR-141-3p		Downregulated in FL vs. with follicular hyperplasia
miR-20b-5p, miR-26a-5p, miR-92b-3p, miR-487b-3p	Cancer cell lines	Upregulated in FL cell lines vs. DLBCL cell lines		[87]
miR-330-3p, miR-106a-5p, miR-210-3p, miR-301 isomiRs, miR-338-5p	FFPE tissues	Upregulated in FL vs. non- neoplastic lymph nodes	Diagnosis	[54]
miR-149-5p, miR-139-5p		Downregulated in FL vs. non- neoplastic lymph nodes
miR-16-5p, miR-17-5p, miR-26a-5p, miR-29a-3p, let-7d-5p, let-7g-5p, let-7i-5p	Cancer cell lines	Downregulated in FL cell lines vs. CD19+ negatively- selected B cells		[87]
miR-144-3p, miR-431-5p	FL biopsies and blood samples	Upregulated in relapsed FL patients	Prognosis, prediction of disease progression	[88]
miR-376b-3p		Downregulated in non-relapsed FL patients

Abbreviations: DLBCL, diffuse large B-cell lymphoma; FFPE, formalin-fixed, paraffin-embedded.